Exploring the Evolving Treatment Landscape for Advanced Hepatocellular Carcinoma
Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.
Andrew X. Zhu, MD, PhD, professor of medicine at the Harvard Medical School and director of Liver Cancer Research at the Massachusetts General Hospital Cancer Center, discusses the evolving treatment landscape for patients with hepatocellular carcinoma (HCC).
For patients with advanced HCC, sorafenib (Nexavar) dominated the field for many years, according to Zhu. The multi-targeted tyrosine kinase inhibitor (TKI) lenvatinib (Lenvima) later joined the field as an alternative single-agent treatment option for patients with advanced HCC. This provided a second option for the frontline setting, and for a long time, clinical trials were unable to demonstrate better activity with other agents or regimens than single-agent sorafenib.
The combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) was able to demonstrate superiority compared with sorafenib in terms of overall survival more recently, and the combination received approval in May 2020.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
